Lantern Pharma (NASDAQ: LTRN) announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR(R) artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
To view the full press release, visit https://ibn.fm/LRGUo
About Lantern Pharma Inc.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai , Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]
BioMedWire is powered by IBN